ATE218139T1 - Xanthin-derivate - Google Patents

Xanthin-derivate

Info

Publication number
ATE218139T1
ATE218139T1 AT95909968T AT95909968T ATE218139T1 AT E218139 T1 ATE218139 T1 AT E218139T1 AT 95909968 T AT95909968 T AT 95909968T AT 95909968 T AT95909968 T AT 95909968T AT E218139 T1 ATE218139 T1 AT E218139T1
Authority
AT
Austria
Prior art keywords
lower alkyl
adenosine
different
same
represents hydrogen
Prior art date
Application number
AT95909968T
Other languages
German (de)
English (en)
Inventor
Fumio Suzuki
Nobuaki Koike
Junichi Shimada
Joji Nakamura
Shizuo Shiozaki
Shigeto Kitamura
Shunji Ichikawa
Hiroshi Kase
Hiromi Nonaka
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE218139T1 publication Critical patent/ATE218139T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95909968T 1994-02-23 1995-02-23 Xanthin-derivate ATE218139T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2573694 1994-02-23
PCT/JP1995/000267 WO1995023148A1 (en) 1994-02-23 1995-02-23 Xanthine derivative

Publications (1)

Publication Number Publication Date
ATE218139T1 true ATE218139T1 (de) 2002-06-15

Family

ID=12174110

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909968T ATE218139T1 (de) 1994-02-23 1995-02-23 Xanthin-derivate

Country Status (7)

Country Link
US (1) US5703085A (2)
EP (1) EP0698607B1 (2)
AT (1) ATE218139T1 (2)
AU (1) AU1823895A (2)
CA (1) CA2161011A1 (2)
DE (1) DE69526822T2 (2)
WO (1) WO1995023148A1 (2)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0814809B1 (en) * 1994-12-13 2003-08-13 Euroceltique S.A. Aryl thioxanthines
DE69834500T2 (de) * 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
CA2439222C (en) * 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
FR2814077A1 (fr) * 2000-09-20 2002-03-22 Inst Nat Sante Rech Med Utilisation de modulateurs de recepteurs a l'adenosine pour reguler la fonction des netrines et/ou de leurs recepteurs
ES2686123T3 (es) 2002-01-28 2018-10-16 Kyowa Hakko Kogyo Co., Ltd Antagonistas del receptor A2A para su uso en el tratamiento de trastornos del movimiento
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
WO2004011010A1 (en) * 2002-07-29 2004-02-05 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
JPWO2005056016A1 (ja) * 2003-12-09 2007-07-05 協和醗酵工業株式会社 高次脳機能障害の予防および／または治療剤
EP1738766A4 (en) * 2004-03-30 2010-05-12 Kyowa Hakko Kirin Co Ltd MEANS FOR THE PREVENTION AND / OR TREATMENT OF DISEASES OF CHRONIC / BONE PAIN
CA2583185A1 (en) 2004-10-20 2006-04-27 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
PL1989214T3 (pl) 2006-02-03 2017-07-31 Gilead Sciences, Inc. Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
JP2010502649A (ja) * 2006-09-01 2010-01-28 シーブイ・セラピューティクス・インコーポレイテッド 心筋層画像化法中の患者の耐性を増加させるための方法および組成物
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
MX2009006346A (es) * 2006-12-22 2010-03-03 Sanol Arznei Schwarz Gmbh Derivados de 8-etinilxantina como antagonistas de receptores de a2a selectivos.
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
EP2099360A2 (en) * 2007-01-03 2009-09-16 CV Therapeutics Inc. Myocardial perfusion imaging
US8349846B2 (en) * 2008-01-11 2013-01-08 Glenmark Pharmaceuticals, S.A. Fused pyrimidine derivatives as TRPV3 modulators
US8119647B2 (en) * 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
EP2344145A1 (en) * 2008-09-29 2011-07-20 Gilead Sciences, Inc. Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods
US10184028B2 (en) 2016-01-11 2019-01-22 Industrial Technology Research Institute Method for preparing a polymer
US9994679B2 (en) * 2016-01-11 2018-06-12 Industrial Technology Research Institute Polymerization process of polyarylene sulfide
US10287396B2 (en) 2016-01-11 2019-05-14 Industrial Technology Research Institute Polymer
US10377705B2 (en) 2016-01-11 2019-08-13 Industrial Technology Research Institute Method for preparing polyarylene sulfide (PAS) monomer
CN111333648B (zh) * 2019-04-24 2021-05-11 东莞市东阳光新药研发有限公司 8-取代的芳香环乙烯基黄嘌呤衍生物及其用途
CN113248505B (zh) * 2021-06-09 2021-09-21 南京安杰新生物医药有限公司 伊曲茶碱去甲基杂质的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006976A1 (en) * 1990-10-18 1992-04-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivative
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
CA2116967C (en) * 1992-07-08 2003-08-19 Fumio Suzuki Antidepressants
DE4325254A1 (de) * 1992-08-10 1994-02-17 Boehringer Ingelheim Kg Unsymmetrisch substituierte Xanthine
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
CA2112031A1 (en) * 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists

Also Published As

Publication number Publication date
EP0698607A4 (2) 1996-03-27
EP0698607A1 (en) 1996-02-28
EP0698607B1 (en) 2002-05-29
US5703085A (en) 1997-12-30
DE69526822T2 (de) 2003-01-23
CA2161011A1 (en) 1995-08-31
WO1995023148A1 (en) 1995-08-31
AU1823895A (en) 1995-09-11
DE69526822D1 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
DE69526822D1 (en) Xanthin-derivate
ATE257156T1 (de) (1,2,4)triazolo(1,5-c)pyrimidin-derivate
EP0784974A4 (en) FIXED DISPERSION OR PREPARATION OF XANTHINE DERIVATIVES AS FIXED DISPERSION
DK0593511T3 (da) Piperidinderivater
MXPA02011417A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos.
EP1063228A4 (en) CYCLOALCENE DERIVATIVES, THEIR MANUFACTURING METHOD AND THE USE THEREOF
HUT53099A (en) Process for producing new tetrahydrobenzimidazole derivatives and pharmaceutical compositions comprising such compounds
BR0111061A (pt) 1-aminoalquil-lactamas substituìdas e seu uso como antagonistas de receptor muscarìnico a61p 21/02
MXPA06001094A (es) Compuestos quimicos.
ATE180482T1 (de) Xanthinderivate zur behandlung der demenz
EA200000336A1 (ru) Антагонисты рецептора витронектина
DE69022279D1 (de) 1-Arylimidazol-Pestizide.
DE69828284D1 (de) Naphthyridinderivate oder salze davon
PH24390A (en) Process for the production of novel arylamine derivatives
EP0680960A4 (en) IMIDAZOLE CONNECTION.
DE69319900D1 (de) N,n'-disubstituierte amidderivate
DE69626624D1 (de) Medikamente gegen trhombocytopenie
DK0489379T3 (da) 5-Amino-5,6,7,8-tetrahydroquinoliner og beslægtede forbindelser, en fremgangsmåde til deres fremstilling og deres anvendels
EP0976735A4 (en) PROCESS FOR PRODUCING PIPERIDINE-CARBOXYLIC ACID AMIDES
AU696458B2 (en) Optically active, substituted phenylalkylamine derivatives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties